Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis
Status:
Withdrawn
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to find out the effects Budesonide, 9 mg daily for one year, has
on patients with Primary Biliary Cirrhosis with features of autoimmune hepatitis.